Gameto

Executive Summary

Gameto is a private biotechnology company leveraging cell engineering to address critical unmet needs in women's reproductive health. Founded in 2020 and headquartered in New York, the company’s lead program, Fertilo, aims to simplify and improve in vitro fertilization (IVF) and egg freezing. By engineering ovarian support cells to create a more natural environment for egg maturation, Fertilo has the potential to reduce the burden of hormonal treatments and increase success rates. The company is currently in Phase 3 clinical development, targeting the substantial market of infertility and elective fertility preservation. With a strong scientific foundation and a clear focus on reproductive aging, Gameto is poised to disrupt the current standard of care if pivotal trials are successful. Gameto's approach represents a paradigm shift in reproductive technology, moving away from high-dose hormone stimulation toward a more physiological cell-based solution. Beyond fertility, the company plans to extend its platform to address menopause and other age-related reproductive conditions. The Phase 3 status suggests that major clinical and regulatory milestones are imminent. If Fertilo demonstrates superior efficacy or safety versus conventional IVF protocols, Gameto could capture significant market share and potentially become an acquisition target for larger fertility or women's health companies. The company’s progress and potential impact make it a compelling investment opportunity in the reproductive health space.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Fertilo clinical trial data readout65% success
• Q1 2027FDA submission for Fertilo50% success
• H2 2026Strategic partnership or licensing deal for Fertilo outside US40% success